| HOME >> MEDICINE >> TECHNOLOGY |
TABLE 73 RENDIX SNAPSHOT 166
RECENTLY FILED/PRE-REGISTRATION COMPOUNDS 167
APIXABAN: BRISTOL-MYERS SQUIBB (BMS)/PFIZER 167
TABLE 74 APIXABAN SNAPSHOT 167
BRILINTA (TICAGRELOR/AZD6140): ASTRAZENECA 168
TABLE 75 BRILINTA SNAPSHOT 169
CERTRIAD (ROSUVASTATIN/ FENOFIBRIC ACID):
ASTRAZENECA/ABBOTT 170
TABLE 76 CERTRIAD SNAPSHOT 170
PHASE II/III COMPOUNDS 171
LCZ696: NOVARTIS 171
TABLE 77 LCZ696 SNAPSHOT 171
EDOXABAN (DU-176B): DAIICHI SANKYO 172
TABLE 78 EDOXABAN (DU-176B) SNAPSHOT 172
SCH 530348 – MERCK 173
TABLE 79 SCH530348 SNAPSHOT 173
TYRISA/DARAPLADIB: GSK 174
TABLE 80 TYRISA SNAPSHOT 174
BETRIXABAN: PORTOLA/MERCK 175
TABLE 81 BETRIXABAN SNAPSHOT 176
PIPELINE ANALYSIS BY COMPANY 177
TABLE 82 PFIZER'S CARDIOVASCULAR PIPELINE 177
TABLE 83 SANOFI-AVENTIS' CARDIOVASCULAR PIPELINE 177
TABLE 84 NOVARTIS' CARDIOVASCULAR PIPELINE 177
TABLE 85 MERCK'S CARDIOVASCULAR PIPELINE 178
TABLE 86 BMS' CARDIOVASCULAR PIPELINE 178
TABLE 87 ASTRA-ZENECA'S CARDIOVASCULAR PIPELINE 178
COMPANY PROFILES 179
SUMMARY 179
TABLE 88 COMPANY REVENUE AND MARKET SHARE ANALYSIS,
THROUGH 2010 ($ MILLIONS) 179
TABLE 89 MARKET FORECAST BY COMPANY, THROUGH 2015 ($
MILLIONS) 180
ASTRAZENECA 181
Business Overview 181
Leading Products 181
Crestor 181
Atacand 182
Certriad 182
Corporate Strategy 182
BRISTOL-MYERS SQUIBB COMPANY 183
Business Overview 183
Leading Products 183
Plavix 183
Apixaban 183
Corporate Strategy 183
MERCK & CO, INC 184
Business Overview 184
Leading Products 184
Vytorin 184
Zetia 185
Cozaar 185
Hyzaar 186
Zocor 186
Corporate Strategy 186
PFIZER, INC 187
Bus
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |